Ablynx demonstrates nebulisation-robust RSV nanobody
This article was originally published in Scrip
Executive Summary
The completion of Ablynx' Phase I study with ALX-0171 marks a significant proof of concept for the pulmonary delivery of the company's nanobody technology. Ablynx said that Phase I data showed that the product, a trivalent molecule, could be administered "via nebulisation directly into the lung in a clinical trial setting, confirming its potential as a first-in-class therapy to treat respiratory syncytial virus (RSV) infections".
You may also be interested in...
Topotarget reconfirms mid-2013 US NDA for belinostat as it looks to Q3 milestone
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca wins EU approval of rare thyroid cancer drug vandetanib
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Solid but not spectacular: Victoza's weight loss verdict in non-diabetics
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.